GB792978A - Improvements in or relating to streptomycin salts - Google Patents

Improvements in or relating to streptomycin salts

Info

Publication number
GB792978A
GB792978A GB1776/56A GB177656A GB792978A GB 792978 A GB792978 A GB 792978A GB 1776/56 A GB1776/56 A GB 1776/56A GB 177656 A GB177656 A GB 177656A GB 792978 A GB792978 A GB 792978A
Authority
GB
United Kingdom
Prior art keywords
streptomycin
salt
inositol
phytate
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1776/56A
Inventor
Frank Harold Buckwalter
Edmund Stanley Granatek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Laboratories Inc
Original Assignee
Bristol Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Laboratories Inc filed Critical Bristol Laboratories Inc
Priority to GB1776/56A priority Critical patent/GB792978A/en
Publication of GB792978A publication Critical patent/GB792978A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds

Abstract

The invention relates to a salt of streptomycin and a phosphorylated inositol, especially one containing three molecules of streptomycin per molecule of phytic acid. The salt may be hydrated or anhydrous. Where free acid groups are available for further salt formation, non-toxic metal ions such as sodium, potassium, ammonium, calcium and magnesium may be present. The phytic acid (inositol hexaphosphoric acid) may be replaced by other inositol phosphoric acids such as the tri- and tetraphosphoric acid. It is preferred to react a water-soluble phytate, e.g. sodium phytate, with a water-soluble salt of streptomycin, e.g. streptomycin sulphate, in aqueous solution at a pH of 7 to 8, preferably after a preliminary treatment with carbon. Streptomycin phytate is therapeutically active, non-toxic and relatively insoluble in water. It is used medicinally (see Group VI) and in the recovery of streptomycin from aqueous solution.ALSO:A therapeutic preparation in the form of a powder, tablet, capsule or aqueous or oily suspension for oral or parenteral use, comprises a salt of streptomycin and a phosphorylated inositol, e.g. streptomycin phytate (see Group IV (b)) with or without the addition of other medicaments. An edible oil such as coconut oil or an injectable oil such as peanut oil, as such or gelled with aluminium monostearate, forms the vehicle for the oily suspensions. Optional ingredients are (a) suspending agents such as sodium carboxymethyl cellulose, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, gum tragacanth, gelatine, pectin, alginates, dextrans, gum karaya, lecithin, polyoxyalkylene derivatives, glyceryl monostearate, inositol phosphoric acids and their non-toxic salts; (b) buffers such as sodium citrate or sodium phosphate; (c) preservatives, e.g. phenol, cresol, alkyl esters of p-hydroxy benzoic acid; (d) other pharmaceutical adjuvants. The particle size of the streptomycin phylate may be varied. Specified other medicaments are anti-histamines, sulpha drugs, vitamins, lipotropic agents, stimulants, analgesics, laxatives, sedatives and antibiotics such as potassium benzyl penicillin. The streptomycin phylate particles may be coated with a suspending agent such as lecithin.
GB1776/56A 1956-01-18 1956-01-18 Improvements in or relating to streptomycin salts Expired GB792978A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1776/56A GB792978A (en) 1956-01-18 1956-01-18 Improvements in or relating to streptomycin salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1776/56A GB792978A (en) 1956-01-18 1956-01-18 Improvements in or relating to streptomycin salts

Publications (1)

Publication Number Publication Date
GB792978A true GB792978A (en) 1958-04-09

Family

ID=9727788

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1776/56A Expired GB792978A (en) 1956-01-18 1956-01-18 Improvements in or relating to streptomycin salts

Country Status (1)

Country Link
GB (1) GB792978A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6278004B1 (en) 1996-11-06 2001-08-21 Aventis Pharma Deutschland Gmbh Stabilized phospholipidic composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6278004B1 (en) 1996-11-06 2001-08-21 Aventis Pharma Deutschland Gmbh Stabilized phospholipidic composition

Similar Documents

Publication Publication Date Title
CA1108622A (en) Metronidazole phosphate and salts
EP0183527B1 (en) Absorbable calcitonin medicament
EP0216459A1 (en) 9-Substituted guanine monohydrates
JPS61151125A (en) Dihydrocodeine/ibuprofen drug composition and method
GB1378348A (en) Orally administered drug composition for therapy in the treatment of narcotic drug addiction
JPS5946947B2 (en) (+) Catechin salt
IE39281B1 (en) Compisitions for radiographic scanning
US2791609A (en) Tetracycline metallo-phosphate complexes and method preparation
US2795528A (en) Therapeutic composition containing a tetracycline and a phosphate other than orthophosphate
IE903717A1 (en) S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset hastened enhanced analgesics
EP0145209B1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
JPH09110700A (en) Medicinal composition
US2816059A (en) N-[beta-(o-chlorophenyl)-beta-(hydroxy)-ethyl] isopropyl amine, salts thereof, and compositions containing same
ES460098A1 (en) Derivatives of penicillanic acid
GB792978A (en) Improvements in or relating to streptomycin salts
JPS5817167B2 (en) Pharmaceutical composition with antiviral action
CN105884827B (en) Pyrimidine amide derivatives and its salt
PT86644B (en) Process for the preparation of dry formulations containing a diclofenac salt
US2710860A (en) Nikethamide adenylate
JPH08295637A (en) Local administrative agent for oral cavity
US3697563A (en) (3,4,5-trimethoxy-benzamido)-alkanoic acids for prophylaxis and treatment of cardiac disorders
KR890002128A (en) Soluble derivatives of silvibin, methods for their preparation and pharmaceutical compositions containing them
EP0030023A3 (en) A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine
US3755599A (en) Methods for relieving bronchospasm with prostaglandin a compounds
US3965167A (en) Crystalline ammonium N-acetyl-L-cysteinate and mucolytic process